LANCE Precision Medicine Platform

Landos is leveraging its AI-based integrated computational LANCE platform to discover and develop a pipeline of potentially first-in-class oral small molecule therapeutic candidates with differentiated profiles designed to address autoimmune, inflammatory, metabolic, and other diseases. The LANCE platform has enabled Landos to identify seven novel targets across thirteen indications to date that have the potential to restore the immune tolerance for patients with autoimmune disease

Since inception, Landos has successfully cleared four INDs with the FDA. Landos Biopharma expects to identify additional novel targets and develop new product candidates for indications such as lupus, rheumatoid arthritis, Nonalcoholic steatohepatitis (NASH), type 1 diabetes, multiple sclerosis, Alzheimer’s disease, diabetic nephropathy, asthma, psoriasis, Eosinophilic Esophagitis (EoE) and Chronic Obstructive Pulmonary Disease (COPD).

Over 10,000 Potential Target

Section 1
Omics patient data from multiple sources: Responders vs. non-responders, active disease vs. remission
Input
Identify blind spots and linkages in immunometabolic pathways
80-100
TARGET PATHWAYS
In Silico
Use AI-based filter for druggability
Conduct multi-scale pathway modeling
(ODE & ABM)
5-10
TARGET PATHWAYS
In Silico
Leverage CRISPR, siRNA, shRNA experimental results with primary human and other cells
2-3
TARGET PATHWAYS
In Vivo
Characterize phenotype of knock-out mice and investigate effects in multiple animal models IBD, SLE MS, T1D

Lance Platform

Accelerated Drug Development and Clinical Capabilities

SEVEN NOVEL IMMUNOMETABOLIC TARGETS
BT-11
Discovery
IND
Initiation of
Phase 1
Phase 2
ready
Phase 3
24 Months
30 Months
NX-13
BT-104
BT-111
NX-66
PX-69
NX-73
Discovery
IND
Initiation of
Phase 1
Phase 2
ready
Phase 3
18 Months
(for NX-13, all others projected)
24 Months
(projected)

Number of IND Filings

4
INDs to date
13+
INDs in 6 years
Using LANCE, we project an ability to file at least 3 INDs in 2021 and 6 INDs in 2022-2025

Foundational Pillars:

  • Target well-conserved and stable immunometabolic processes that could prove a successful strategy for therapeutic efficacy
  • Prioritize patient safety
  • Design targets to restore immune tolerance that may drive more durable clinical response and remission
  • Identify novel pathways with promising potential to innovate the treatment of autoimmune disease